Evidence map›Paper›PMID 37188045›Full record

ArticleHippokratia

Total costs of inpatient treatment for COVID-19 in a tertiary hospital in Serbia.

P S Sazdanovic, S Milisavljevic, D R Milovanovic, S M Jankovic, D Baskic, Ristic Ignjatovic, Zecevic Ruzic, Lucic Tomic, N Djordjevic, D Jovanovic and 4 more

Abstract read
PubMed Full text at PMC
In one paragraph

Article in Hippokratia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

P S SazdanovicFaculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
S MilisavljevicFaculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
D R MilovanovicFaculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
S M JankovicFaculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
D BaskicFaculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Ristic IgnjatovicFaculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Zecevic RuzicFaculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Lucic TomicFaculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
N DjordjevicFaculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
D JovanovicFaculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
A StojkovicFaculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
T LazarevicFaculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Cvetkovic BegovicUniversity Clinical Centre Kragujevac, Kragujevac, Serbia.
M J KosticFaculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOur study aimed to identify the total costs of inpatient treatment for coronavirus disease 2019 (COVID-19) in a tertiary institution in Serbia, an upper-middle-income country in Southeast Europe.

methodsAn observational, retrospective, cost-of-illness study was performed from the perspective of the National Health Insurance Fund and included a cohort of 78 females and 118 males admitted to the COVID-19 ward units of a tertiary center during the first wave of the pandemic.

resultsThe median of the total costs in the non-survivors subgroup (n =43) was 3,279.16 Euros [interquartile range (IQR): 4,023.34; range: 355.20-9,909.61) which is higher than in the survivors (n =153) subgroup 747.10 Euros (IQR: 1,088.21; 46.71-3,265.91). The cut-off value of 156.46 Euros regarding the total costs per day was estimated to have 95.3 % sensitivity and 91.5 % specificity for predicting patients' dismal prognosis, with the area under the curve (AUC) of 0.968 (95 % confidence interval: 0.940-0.996, p <0.001).

conclusionsDirect medical inpatient treatment costs for COVID-19 represent a significant economic burden. The link between increased costs and an ultimate unfavorable outcome should be further explored.HIPPOKRATIA 2022, 26 (2):62-69.

Indexed as

Coronaviruscost of illnessCOVID-19direct costsinpatientspandemicSerbia

Identifiers

PMID37188045
PMCPMC10177856

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.